Best Pain Management Companies in California, United States
The 89 best Pain Management companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nalu Medical.
Ranked: Best Pain Management companies in California
| # | Company | Disclosed funding | Last round | Employees | Founder | Web popularity | SEO maturity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Nalu Medical Developer of a neurostimulation system for managing intractable chronic pain | $231M | 30 mo ago | 166 | Keegan Harper Founder | Top 5M | rich | 161 patents Implantable neuromodulation devices delivering advanced stimulation waveforms for pain therapy | — |
| 2 | Zogenix Developing drug delivery systems for treatment of CNS diseases | $149M | 104 mo ago | 159 | Bret Megargel Co-Founder | — | — | 151 patents Novel CNS and mitochondrial therapeutics: prodrugs, formulations, and seizure‑related compounds. | — |
| 3 | Myoscience Non-opioid pain relief treatment using advanced cold technology | $148M | 91 mo ago | 687 | — | — | — | 167 patents Patents concentrated in health & consumer products | — |
| 4 | Zosano Pharma Developer of transdermal drug delivery systems for a broad range of therapeutic indications | $147M | 92 mo ago | 40 | — | — | — | — | — |
| 5 | Allay Therapeutics Developer of drugs for post-surgical pain management 42Funding top 18%Moat top 39%Market bottom 44%Global bottom 38% All 5 signals ▾Fundingtop 18% Moattop 39% Marketbottom 44% Globalbottom 38% Newsbottom 21% Funding: Raised $102M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 42/100 | $102M | 12 mo ago | 50 | — | — | — | — | — |
| 6 | XenoPort Provider of biopharmaceutical products for neurological disorders and pain management | $101M | 163 mo ago | 156 | — | — | — | 722 patents Sustained‑release oral formulations of fumarate‑based pharmaceutical compounds | — |
| 7 | Heron Therapeutics Pharmaceutical company focused on acute care and oncology with innovative therapies | $86M | 35 mo ago | 21 | — | Top 10M | rich | 202 patents Advanced drug delivery devices and pharmaceutical formulation technologies for injectable therapies | 2 job openings |
| 8 | Concentric Analgesic Developer of platform for developing pro-drugs | $85M | 85 mo ago | 24 | John Donovan Co-Founder & President | — | — | — | — |
| 9 | AEON BioPharma Provider of bio-therapeutics to treat nervous system-related conditions | $84M | 46 mo ago | 9 | Marc Forth President and Chief Executive Officer | Top 50M | rich | 78 patents Botulinum toxin therapeutics for migraine, pain, autonomic and cardiovascular disorders | — |
| 10 | Afferent Pharmaceuticals Targeting sensitized nerves to treat chronic & debilitating neurogenic disorders. | $78M | 131 mo ago | 5 | — | — | — | 130 patents P2X3/P2X2/3 antagonist pyrimidine drugs for chronic cough therapy | — |
| 11 | NeurogesX Novel pain management therapies | $78M | 163 mo ago | 35 | — | — | — | 96 patents Patents concentrated in health & consumer products | — |
| 12 | Satsuma Pharmaceuticals Developer of therapeutics for migraine sufferers | $74M | 63 mo ago | 24 24 → 26 (+8%) | Ryoichi Nagata CEO | Top 10M | rich | — | — |
| 13 | XWPharma Developer of drugs for treating neurological disorders like epilepsy, Parkinson's & others | $58M | 69 mo ago | 15 | Leonard Blum President & CEO | — | — | 22 patents Formulating gamma‑hydroxybutyric acid derivatives and excipient granulation for drug delivery | — |
| 14 | Cosmederm Bioscience Developing small molecule for neuropathic pain management. | $50M | 140 mo ago | 10 | Gary Hahn Founder & CSO | — | — | — | — |
| 15 | MAP Pharmaceuticals Developer of inhalation migraine therapies | $50M | 230 mo ago | 144 | Paul Boyd Founder & Director | — | — | 266 patents Migraine drug formulations and inhalation delivery devices for dihydroergotamine | — |
| 16 | Victory Pharma Prescription pharmaceutical products for the treatment of pain and related conditions. | $45M | 207 mo ago | 37 | — | — | — | — | — |
| 17 | Carbylan Therapeutics using polymers of hyaluronic acid for pain management. | $43M | 135 mo ago | 7 | — | — | — | — | — |
| 18 | Roxro Pharma Develops drugs for acute pain | $43M | 228 mo ago | — | Roberto Rosenkranz CEO | — | — | — | — |
| 19 | Neumentum Developing non-opioid pain management solutions for acute and chronic pain | $41M | 37 mo ago | 8 | Joseph Pergolizzi Co-Founder | — | — | 5 patents Topical analgesic and anti-inflammatory pharmaceutical formulations | — |
| 20 | Bonti Developing botulinum neurotoxins for the treatment of musculoskeletal pain | $36M | 100 mo ago | 10 | Susan Abushakra Co-Founder & CMO | — | — | 84 patents Therapeutic botulinum toxin formulations and production methods for medical and cosmetic use. | — |
| 21 | Adynxx Developer of oligonucleotide technology for developing chronic pain management drugs | $36M | 80 mo ago | 7 | — | — | — | 66 patents Nucleic‑acid‑based therapeutics and delivery systems for pain relief via gene expression modulation | — |
| 22 | EicOsis Developing safer pain and inflammation treatments by restoring the body's natural healing | $31M | 14 mo ago | 14 14 → 7 (-50%) | Robert Gregoire Co-Founder & CEO | — | — | 24 patents Solid-form pharmaceutical innovations for epoxide hydrolase and kinase inhibitor therapies | — |
| 23 | SiteOne Therapeutics Sodium ion channel 1.7 (Na 1.7) inhibitors for acute and chronic pain. | $24M | 13 mo ago | — | John Mulcahy Co-Founder & CEO | — | — | — | — |
| 24 | DURECT Developer of therapeutics for chronic diseases and pain | $20M | — | 79 79 → 73 (-8%) | James Brown Co-Founder & CEO | Top 50M | rich | 839 patents Oxygenated cholesterol sulfate derivatives for therapeutic formulations and liver disease treatments | — |
| 25 | Navega Therapeutics Developer of gene therapy products for chronic pain management | $15M | 13 mo ago | 10 | Prashant Mali Co-Founder | — | — | — | — |
| 26 | Epiodyne Developing opioid medicines for pain management and opioid use disorder | $14M | 50 mo ago | 4 | Douglas Crawford CEO | — | — | 25 patents Design and synthesis of novel opioid receptor ligands for pain and addiction therapeutics. | — |
| 27 | Xalud Therapeutics Gene therapy company restoring immune balance to treat chronic inflammation | $12M | 74 mo ago | 19 | — | — | — | — | — |
| 28 | Abide Therapeutics Serine hydrolase inhibitors for pain management | $12M | 147 mo ago | 47 | — | — | — | 235 patents Patents concentrated in chemistry & materials | — |
| 29 | Raft Pharmaceuticals Developer of therapeutics to treat neuroinflammation | $10M | 14 mo ago | — | Tony Yaksh Co-Founder | — | — | — | — |
| 30 | Ivivi Health Sciences Electrotherapy for accelerated postoperative healing, pain & edema reduction | $10M | 184 mo ago | — | Steven Gluckstern ex-Co-Founder | — | — | — | — |
| 31 | Oska Wellness Pain relief devices using PEMF technology for active, pain-free living | $6M | 83 mo ago | 5 | — | Top 10M | rich | — | — |
| 32 | Semnur Pharma Biopharmaceutical innovator focused on non-opioid pain management solutions | $6M | 154 mo ago | 1 | — | — | — | — | — |
| 33 | Cerephex Non-invasive brain stimulation to manage central pain | $6M | 164 mo ago | 8 | Rob Ford Co-Founder | — | — | 26 patents Patents concentrated in health & consumer products | — |
| 34 | NeuraLace Medical Non-invasive neuromodulation for chronic neuropathic pain relief and improved patient outcomes | $6M | 84 mo ago | 19 | — | Top 10M | rich | — | 1 launch |
| 35 | Trigemina Nasally administered analgesics | $5M | 156 mo ago | 12 | William John CEO | — | — | 50 patents Magnesium‑enhanced oxytocin pharmaceutical formulations for obstetric and analgesic applications | — |
| 36 | Claritas Pharmaceuticals Developer of vaccine for preventing COVID-19 and pain | $5M | 53 mo ago | 6 | — | — | — | — | — |
| 37 | Bexson Biomedical Developer of ketamine therapies for chronic and acute pain disorders | $5M | 64 mo ago | 6 | Jeffrey Becker Co-Founder | — | — | 43 patents Pharmaceutical salt formulations with complexing agents and NMDA receptor antagonist drugs. | — |
| 38 | Transdel Pharmaceuticals Clinical-stage specialty pharma developing topical formulations | $4M | 187 mo ago | — | John N Bonfiglio CEO | — | — | — | — |
| 39 | Realeve Developer of a device for the treatment of cranial autonomic disorders | $3M | 33 mo ago | 21 | Jon Snyder CEO | — | — | 16 patents Modulating tissue barrier porosity for drug delivery and neurostimulator implantation techniques. | — |
| 40 | Peptide Logic Provider of peptide therapeutics | $3M | 80 mo ago | 11 | Pierre Riviere Founder & CEO | — | — | — | — |
| 41 | Anesiva Small molecule therapeutics for chronic pain. Deadpooled | $3M | 208 mo ago | 33 | Michael Kranda CEO & President | — | — | 14 patents Patents concentrated in chemistry & materials | — |
| 42 | Elysium Therapeutics Developing innovative solutions to combat opioid overdose and reduce opioid abuse | $2M | 4 mo ago | 2 | Alex Sturmer President | — | — | — | — |
| 43 | BioPhotas LED light therapy devices for skin, pain, hair, and body | $2M | 120 mo ago | 32 | — | — | — | 37 patents Portable phototherapy devices for medical light treatment of skin and wounds | — |
| 44 | WinSanTor Developing nerve-regenerating treatments for peripheral neuropathy, improving patient lives | $783K | 14 mo ago | 5 | Nigel Calcutt Co-Founder | Top 5M | rich | 25 patents Topical pharmaceutical formulations for peripheral neuropathy pain and sexual sensory disorder treatment. | — |
| 45 | TrioWave Developer of a biostimulation device for pain management and aesthetics. | $400K | 146 mo ago | 1 | Huiyou Zhu Founder | — | — | 5 patents Electrotherapy waveform generation, control, and personalized therapy device power management | — |
| 46 | Thimble Bioe Wearable patch for pain management | $200K | 149 mo ago | — | Shaun Rahimi Founder & CEO | — | — | — | — |
| 47 | Abalone Bio Developer of antibody drugs for pain management and cancer | $125K | 26 mo ago | 20 | Richard Yu Co-founder and CEO | — | — | — | — |
| 48 | Enso Relief Develops a wearable neuromodulation device for relief from pain | $120K | 108 mo ago | 93 | — | — | — | — | — |
Top 12 Pain Management companies in California
#1
Series D · Menlo Park, California · founded 2017 · 50 employees$101.9Mraised▾
Developer of drugs for post-surgical pain management. The company's proprietary technology platform combines non-opioid analgesics and biopolymers to create dissolvable candidates that deliver pain relief within a targeted site. The company's lead candidate is ATX-101 for post surgical knee rehabilitation. Other candidates include ATX-201 and ATX-301 injectables for on-demand delivery.
- Jun 2025Venture Debt—
- Jan 2025Series D$57.5M
- Dec 2022Series D—
- Sep 2021Series C$86.9M
#2
Series A · San Francisco, California · founded 2013 · 2 employees$2.4Mraised▾
Developing innovative solutions to combat opioid overdose and reduce opioid abuse. This therapeutics company is dedicated to establishing new safety standards in the pharmaceutical industry, specifically addressing the opioid crisis. They focus on creating Safer Medicines that Alleviate Risks and Trauma (SMART) products. Their lead products include a rescue agent designed for synthetic opioid overdoses and an oral overdose protection system. These solutions aim to reduce opioid use disorder, prevent fatal overdoses, and effectively manage pain. The company leverages its expertise to develop novel chemical entities with the potential to receive breakthrough technology designation. They are seeking partners to support their mission of reducing suffering from pain, opioid use disorder, and fatal opioid overdose. Their work has a significant social impact, addressing a critical public health issue.
- Jan 2026Series A$7.5M
- Oct 2022Seed$2.2M
- Mar 2019Seed$215K
- Jun 2018Grant (prize money)$6.2M
#3
Funding Raised · Davis, California · founded 2011 · 14 employees$30.8Mraised▾
Developing safer pain and inflammation treatments by restoring the body's natural healing. The company is focused on transforming inflammation treatment with a novel approach. They are developing new safe and effective oral analgesics and anti-inflammatories by targeting the soluble Epoxide Hydrolase (sEH). This innovative technology aims to address the unmet need for non-addictive pain medications and combat the opioid crisis. The company is advancing its first drug candidate through human clinical trials. Their research explores the potential of sEH inhibitors for various conditions, including neuropathic pain, traumatic brain injury, and Alzheimer's disease. The company collaborates with researchers and institutions to advance scientific understanding and develop innovative therapies. They are committed to improving the lives of those suffering from pain and inflammation through scientific research and clinical development.
- Apr 2025Grant (prize money)$6.8M
- Jan 2025Grant (prize money)$6.8M
- Jul 2022Grant (prize money)$279.1K
- Oct 2019Grant (prize money)$15M
#4
Acquired · San Francisco, California · founded 2010$23.8Mraised▾
SiteOne Therapeutics is focussed on developing pain therapeutics for the treatment of acute and chronic pain. Its therapeutic candidates are selective sodium ion channel 1.7 (Naᵥ1.7) inhibitors based on naturally occurring small molecules. Its lead product for the treatment of moderate to severe pain is in pre-clinical trials Its technology also has additional applications in long-acting analgesics, PET imaging diagnostics for pain and other pain indications.
- Apr 2025Grant (prize money)$1.5M
- Dec 2024Series C$100M
- Mar 2024Series B$6M
- May 2023Grant (prize money)$15M
#5
Funding Raised · San Diego, California · founded 2018 · 10 employees$14.5Mraised▾
Developer of gene therapy products for chronic pain management. The company's novel gene therapy platform to target and imitate the patients with a mutation in the genome where no pain is felt., and apply it to treat pain.
- Apr 2025Grant (prize money)$4.3M
- Apr 2025Grant (prize money)$4.3M
- Apr 2025Grant (prize money)$2.2M
- Sep 2023Grant (prize money)$400K
#6
Funding Raised · San Diego, California · founded 2015$9.6Mraised▾
RAFT Pharmaceuticals has developed therapeutics to treat neuroinflammation. The company has developed RFT-001 that target the lipid rafts to regulate cholesterol transportation in the inflamed neural cells to treat chemotherapy led or nerve injury-induced neuropathic pain and migraine.
- Mar 2025Grant (prize money)$3M
- Sep 2023Grant (prize money)$698K
- Sep 2022Grant (prize money)$500K
- Sep 2022Grant (prize money)$2M
#7
Acquired · Carlsbad, California · founded 2014 · 166 employees$231Mraised▾
Developer of a neurostimulation system for managing intractable chronic pain. The company offers Nalu neurostimulation system which is a micro-implantable pulse generator is used for Spinal Cord Stimulation and Peripheral Nerve Stimulation. The device uses gentle electrical impulses to interrupt pain signals.
- Dec 2023Series E$115.1M
- Oct 2022Conventional Debt$45M
- Feb 2022Series B$104M
- Jul 2015Series A$11.9M
#8
Public · Redwood City, California · founded 1983 · 21 employees$85.7Mraised▾
Pharmaceutical company focused on acute care and oncology with innovative therapies. They are dedicated to improving patient lives through the development and commercialization of best-in-class medicines. Their approach combines innovative science and technologies with established pharmacology to create therapies that address unmet medical needs in both acute care and oncology settings. They offer a portfolio of products and a pipeline of drug candidates designed to advance the standard of care, particularly in areas like postoperative pain management, chemotherapy-induced nausea and vomiting prevention, and postoperative nausea and vomiting. They aim to provide solutions that can help patients spend more time doing the things that matter with the people who matter. They are committed to research and development, seeking to create novel, patient-focused solutions.
- Jul 2023Post IPO$30M
- Aug 2022Post IPO$76.5M
- May 2021Post IPO$150M
- Mar 2018Post IPO$156M
#9
Seed · San Diego, California · founded 2011 · 5 employees$782.9Kraised▾
Developing nerve-regenerating treatments for peripheral neuropathy, improving patient lives. The company focuses on creating disease-modifying treatments for this widespread condition, impacting a significant portion of the global population. They advance scientific breakthroughs from initial discovery and preclinical validation through rigorous clinical trials, aiming for commercialization and partnerships to deliver treatments worldwide. Their process involves identifying promising scientific advancements, guiding innovations through regulatory testing, and bringing approved treatments to patients through commercialization, licensing, and collaboration. The company is dedicated to addressing the unmet needs of individuals burdened by peripheral neuropathy, offering hope for nerve growth and regeneration.
- Apr 2025Grant (prize money)$2M
- Nov 2017Seed$782.9K
#10
Series B · Palo Alto, California · founded 2017 · 8 employees$40.8Mraised▾
Developing non-opioid pain management solutions for acute and chronic pain. The company is dedicated to creating effective and safe alternatives to opioids, addressing the unmet need for pain treatments without the risks of abuse, misuse, and opioid-induced side effects. They focus on developing and commercializing novel non-opioid products to treat pain globally. Their pipeline includes product candidates with the potential to provide analgesics without the risks associated with opioids, offering new alternatives for the treatment of acute and chronic pain in hospital and community settings. The company aims to transform how pain is treated, providing solutions for patients, providers, and payers.
- Apr 2023Series B$16.6M
- Nov 2019Series A$2.7M
- Sep 2019Series A$3M
- Sep 2018Series A—
#11
Public · Newport Beach, California · founded 2018 · 9 employees$84.5Mraised▾
Provider of bio-therapeutics to treat nervous system-related conditions. The company's flagship product is ABP-450 which is 900 kDa pra botulinum toxin A and is used for patients suffering from disabling disorders.
- Aug 2022Post IPO$54.5M
- Sep 2020Series B$30M
#12
Acquired · Redwood City, California · founded 2005 · 687 employees$147.7Mraised▾
Non-opioid pain relief treatment using advanced cold technology, offering immediate and long-lasting pain relief. It uses extreme cold to temporarily stop nerves from sending pain signals, providing an alternative for osteoarthritis knee pain and those considering or unable to have knee replacement surgery. This FDA-cleared treatment can be administered in various settings. It is also used to treat pain in the hip, shoulder, foot, ankle, spine, rib fracture, and mastectomy. The system applies freezing cold to peripheral nerve tissue to block and/or relieve pain.
- Oct 2018Series F$5M
- Mar 2018Series F$30.9M
- Oct 2017Series F$14M
- Sep 2014Series E$8.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Pain Management coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Medical Devices in California is moving
A read on the academic research around Medical Devices in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 110 papers.
UC San Francisco, Berkeley, and USC lead California's medical-device research across soft robotics, surgical simulation, and AR applications, with a cautiously optimistic yet contested tone (stance 0.32).
- University of California, San Francisco20
- University of California, Berkeley14
- University of Southern California13
- University of California San Diego12
- University of California, Los Angeles10
- Robot15
- Surgical robot11
- Computer vision6
- Robotics6
- Robotic surgery3
- Biomedical engineering1→3
- Robot2→4
- Surgical robot3→5
- Food and drug administration1→6
- Patient safety1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.